GlassScriptPhysician profile
Srinivas Battula
NPI 1093729311
$702.23
in general payments reported to CMS, 2019-2025
14 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.72 · 2020: $23.20 · 2021: $63.62 · 2022: $109 · 2023: $212 · 2024: $133 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $198.46 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $74.06 | 2022-2023 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $71.18 | 2024-2025 | Rexulti |
| Lundbeck LLC | $53.04 | 2022-2025 | Rexulti |
| Alkermes, INC. | $52.82 | 2022-2025 | Aristada, Lybalvi |
| Indivior INC. | $46.63 | 2022-2023 | Perseris |
| Vanda Pharmaceuticals INC. | $34.81 | 2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $34.16 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.06 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $30.87 | 2023-2024 | Uzedy |
| Orexo US, INC. | $23.20 | 2020 | |
| Merck Sharp & Dohme LLC | $20.00 | 2023 | Belsomra |
| Noven Therapeutics, LLC | $16.22 | 2024 | Secuado, Xelstrym |
| Mdd US Operations, LLC | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Battula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.